MYGN · Myriad Genetics, Inc. · Stock research

Current Thesis

Since the last update the tape has done one thing: bounced. The post-print low of $3.03 (2026-08-14) held, the 2026-08-21 close was $3.20, and RSI(14) travelled from 19.3 to 58.2 across those five sessions with no company disclosure in between. That is an oversold reading unwinding, and the substance behind the July collapse is unchanged: Q2 revenue $190.7M (-11% YoY, roughly $15.3M under the ~$206M consensus), FY2026 revenue guidance cut to $770–790M from $860–880M, adjusted EBITDA guidance suspended outright (prior $37–49M), all disclosed 2026-07-30. The Street kept marking down into the bounce — Stephens & Co. Maintained Equal-Weight and cut its target to $3 on 2026-08-18, which sits under the 2026-08-21 close. The narrative is dead, dated to 2026-07-30/31 when the $5.75–$6.26 July shelf and the June $3.99 low both went in one session (-47%). What the tape prices now is a reimbursement-and-collections problem with no profitability outlook attached, and nothing dated resolves it before the Q3 report.

Bullish and bearish views on Myriad Genetics, Inc.

The model's bull view on Myriad Genetics, Inc. (MYGN), in brief: Demand did not leave; collection did. Q2 total test volume fell 1% YoY while revenue per test fell 9% (2026-07-30). Hereditary cancer testing was the sharpest version: revenue -13% YoY on volume +8%. Liquidity is not immediately binding. $115M cash and equivalents plus $75M… The bear view: A $90M midpoint guidance cut twelve weeks after a reiteration. Both cases follow in full.

Bull Case

• Demand did not leave; collection did. Q2 total test volume fell 1% YoY while revenue per test fell 9% (2026-07-30). Hereditary cancer testing was the sharpest version: revenue -13% YoY on volume +8%.
• Liquidity is not immediately binding. $115M cash and equivalents plus $75M available under the credit facility, ~$190M total, at the Q2 report (2026-07-30).
• A global HRD licensing deal landed 2026-07-20. Burning Rock Biotech and Myriad announced a technology licensing partnership adding Myriad's prostate Genomic Instability Score (prGIS) to myChoice HRD Plus and licensing the GIS/prGIS algorithms onto Burning Rock's OncoScreen Plus platform for markets beyond China. No upfront, milestone or royalty terms were disclosed, so it is optionality rather than a modelable line.
• The MRD roadmap was pulled forward. On the 2026-05-05 call management moved the Precise MRD colorectal + renal select-customer launch into Q3 2026 from 2027; the 2026-06-23 expansion covered breast/colorectal/renal, and MONITOR-Breast (Future Oncology, 2026-06-23) reported 100% specificity for pCR prediction.
• Prolaris + AI shipped on schedule — live on all U.S. Prolaris biopsy samples from 2026-05-29, with a 2026-07-02 meta-analysis finding the biopsy test adds prognostic information beyond conventional clinical risk categories.
• The marking-down has largely happened. Four reset targets now cluster in a $3.00–$4.00 band: Stephens $3 (2026-08-18), Wells Fargo $3 from $5.50 (2026-08-03), BofA $3.20 from $4, TD Cowen $4 from $6.

Bear Case

• A $90M midpoint guidance cut twelve weeks after a reiteration. FY2026 revenue was reaffirmed at $860–880M on 2026-05-05 and cut to $770–790M on 2026-07-30. Three law-firm investigation notices have followed that sequence: Johnson Fistel 2026-08-04, Bragar Eagel & Squire 2026-08-07, Levi & Korsinsky 2026-08-10.
• Burn widened four-fold quarter on quarter. Adjusted EBITDA -$16.9M in Q2 against -$4.5M in Q1 (2026-05-05), with the FY range withdrawn rather than lowered.
• Cash-collection quality deteriorated in a measurable way: an $11M revenue reduction from changed collection estimates on prior-period tests, plus a $4M write-off of aged receivables.
• Every segment negative in Q2: Cancer Care Continuum $114M (-13% YoY), Prenatal Health $40M (-16%), Mental Health/GeneSight $37M (-3%). GeneSight had grown 24% YoY to $38.3M in Q1 — the fastest line flipped inside one quarter.
• Margin structure reset. Q2 gross margin 66.6%, -460bps YoY; FY adjusted gross-margin guidance cut to 66–67% from 68–69%.
• The freshest sell-side action came after the bounce began and was another cut — Stephens to $3 on 2026-08-18, below the $3.20 close three sessions later.
• Precise MRD enters behind Natera Signatera, Guardant Reveal and Exact Oncodetect, into the same payer-adjudication process that produced the Q2 realization drop.

Setup & Price Structure

• 2026-08-21 close $3.20, 60.9% under the $8.18 52-week high, with a three-month price change of -16.2%.
• The break is not repaired. $3.67 (the post-print after-hours level of 2026-07-30) and $5.37 (that day's regular-session close) are both unreclaimed. The July $5.75–$6.26 consolidation and the June $3.99 low are overhead supply.
• RSI(14) moved 19.3 → 58.2 between 2026-08-14 and 2026-08-21. A 39-point swing off a washed-out reading with no disclosure attached is mechanical. One week of higher lows is too short a sample to call a base.
• Positioning and crowding observables: the coverage clustering around the name since the print has come from law-firm solicitation releases — three between 2026-08-04 and 2026-08-10 — rather than from fundamental research initiations. Two of the four reset price targets sit below the last close. No earnings date falls inside 30 days. No insider open-market purchase appears in the recent filing record; a disclosed officer or director buy would be the cheapest available signal that management treats the reset guide as conservative, and none has surfaced.

Catalyst Calendar (next 30 days)

• No confirmed dated company event falls inside 2026-08-23 → 2026-09-22. No September investor-conference appearance has been announced as of 2026-08-23; the most recent participation release covered the BofA Health Care Conference (2026-05-13) and Goldman Sachs Global Healthcare (2026-06-10).
• ~2026-09-30 (est.) — close of the guided Q3 2026 window for the Precise MRD colorectal/renal select-customer launch. Pulled forward on 2026-05-05 and the only company-controlled deliverable before November.
• ~2026-11-03 (est.) — Q3 2026 results. First read on the reset $770–790M guide and the earliest realistic point to reinstate an adjusted EBITDA outlook.
• Undated — conversion of any investigation notice into a filed complaint with a named class period and lead-plaintiff deadline.

What Would Change Our Mind

The item that would re-open the equity story is a reinstated adjusted EBITDA outlook alongside revenue per test flat or up YoY — that combination would date the Q2 realization drop as timing rather than a permanent reset of the collection rate, and the earliest venue for it is the ~2026-11-03 Q3 report. A launch announcement for Precise MRD colorectal/renal inside the guided Q3 window would show the Ascend efficiency program is not being funded by delaying the pivot. On the other side, a daily close below $3.03 forfeits the 2026-08-14 post-print low and ends the August reflex bounce; the ~2026-09-30 MRD window passing with no launch disclosure would remove the last company-controlled deliverable before November. Any ATM, convertible, shelf takedown or disclosed revolver draw would recast the $190M liquidity figure as a dilution timetable.

Correlation Notes

• Direct payer-friction read-across to the MRD/liquid-biopsy set — Natera, Guardant Health, Exact Sciences. If those names report accelerating MRD volumes in their Q3 prints while Myriad discloses no MRD revenue contribution, the share-loss risk is the live one rather than an industry-wide reimbursement squeeze.
• Prenatal Health (-16% YoY in Q2) tracks NIPT volume and coverage trends; Natera's Panorama commentary is the nearest external check.
• CMS/MolDX coverage determinations and commercial prior-authorization policy move the whole diagnostics panel together; the Q2 call cited higher denial rates and prior-auth requirements by name.
• At a $3.20 close the name behaves like a headline-driven micro-cap: single releases dominate the tape and index-level small-cap risk appetite explains little of the daily range.